生物医学ジャーナル

  • ISSN: 2254-609X
  • ジャーナル h-index: 15
  • 雑誌引用スコア: 5.60
  • ジャーナルのインパクトファクター: 4.85
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • OCLC-WorldCat
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

A Short Note on the Enhanced infectious diseases vaccines

Aaron Marta

The best way to avoid getting the influenza virus is to get vaccinated. In any case, flow occasional flu antibodies are just defensive against firmly paired coursing strains. Our efforts frequently result in mismatches and low vaccine effectiveness, despite extensive monitoring and annual reformulation. As a result, we are still one step behind the rapidly evolving virus. Fortunately, numerous next-generation influenza vaccines are currently in development, making use of a variety of cuttingedge methods to speed up production and broaden protection. The vaccine manufacturing practices that are currently in use, the most recent advancements in influenza vaccine research, and any potential obstacles that need to be overcome are all covered in this overview. The advantages of removing the glycan shield from influenza surface antigens in order to increase vaccine immunogenicity and the potential role that glycol engineering might play in the development of an influenza vaccine are given particular attention. From an industry perspective, the possibility of developing these novel influenza vaccine candidates in the future is discussed.

Keywords Influenza Virus; Glycoengineering; Vaccine